Eesti - eesti - Ravimiamet

elanco animal health gmbh - imidaklopriid - täpilahus - 80mg 0.8ml 0.8ml 4tk

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - montelukast - närimistablett - 5mg 84tk; 5mg 28tk; 5mg 30tk; 5mg 140tk; 5mg 7tk; 5mg 50tk; 5mg 90tk; 5mg 14tk

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - montelukast - närimistablett - 4mg 28tk; 4mg 50tk; 4mg 56tk; 4mg 200tk; 4mg 10tk; 4mg 20tk; 4mg 14tk; 4mg 7tk; 4mg 100tk

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - montelukast - õhukese polümeerikattega tablett - 10mg 100tk; 10mg 84tk; 10mg 56tk; 10mg 98tk; 10mg 200tk; 10mg 20tk; 10mg 140tk; 10mg 50tk; 10mg 90tk; 10mg 28tk; 10mg 30tk; 10mg 14tk; 10mg 7tk

Eesti - eesti - Ravimiamet

koanaa healthcare gmbh - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk

Eesti - eesti - Ravimiamet

koanaa healthcare gmbh - pemetrekseed - infusioonilahuse kontsentraadi pulber - 100mg 1tk

Eesti - eesti - Ravimiamet

ge healthcare buchler gmbh & co. kg - naatriumjodiid (131i) - kõvakapsel - 5tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - levodopa+karbidopa - tablett - 100mg+25mg 100tk; 100mg+25mg 20tk; 100mg+25mg 200tk

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - levodopa+karbidopa - tablett - 250mg+25mg 20tk; 250mg+25mg 120tk; 250mg+25mg 200tk; 250mg+25mg 100tk; 250mg+25mg 60tk